Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.
The pathogenicity of Mycobacterium ulcerans, the agent of Buruli ulcer, depends on the cytotoxic exotoxin mycolactone. Little is known about the immune response to this pathogen. Following the demonstration of an intracellular growth phase in the life cycle of M. ulcerans, we investigated the production of tumor necrosis factor (TNF) induced by intramacrophage bacilli of diverse toxigenesis/virulence, as well as the biological relevance of TNF during M. ulcerans experimental infections. Our data show that murine bone marrow-derived macrophages infected with mycolactone-negative strains of M. ulcerans (nonvirulent) produce high amounts of TNF, while macrophages infected with mycolactone-positive strains of intermediate or high virulence produce intermediate or low amounts of TNF, respectively. These results are in accordance with the finding that TNF receptor P55-deficient (TNF-P55 KO) mice are not more susceptible than wild-type mice to infection by the highly virulent strains but are more susceptible to nonvirulent and intermediately virulent strains, demonstrating that TNF is required to control the proliferation of these strains in animals experimentally infected by M. ulcerans. We also show that mycolactone produced by intramacrophage M. ulcerans bacilli inhibits, in a dose-dependent manner, but does not abrogate, the production of macrophage inflammatory protein 2, which is consistent with the persistent inflammatory responses observed in experimentally infected mice.
Torrado
Egídio
E
Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, 4710-057 Braga, Portugal.
Adusumilli
Sarojini
S
Fraga
Alexandra G
AG
Small
Pamela L C
PL
Castro
António G
AG
Pedrosa
Jorge
J
D000818:Animals; D001427:Bacterial Toxins / Q000276:immunology*; D002478:Cells, Cultured; D054426:Chemokine CXCL2; D004195:Disease Models, Animal; D005260:Female; D005528:Foot / Q000473:pathology; D018942:Macrolides; D008264:Macrophages / Q000276:immunology / Q000382:microbiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D015846:Monokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D009165:Mycobacterium Infections, Nontuberculous / Q000276:immunology* / Q000382:microbiology; D019911:Mycobacterium ulcerans / Q000254:growth & development / Q000276:immunology* / Q000472:pathogenicity*; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000235:genetics; D053319:Tumor Necrosis Factor Decoy Receptors / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000276:immunology*; D014774:Virulence
D001427:Bacterial Toxins; D054426:Chemokine CXCL2; D018942:Macrolides; D015846:Monokines; D047888:Receptors, Tumor Necrosis Factor, Type I; D053319:Tumor Necrosis Factor Decoy Receptors; D014409:Tumor Necrosis Factor-alpha; C117218:mycolactone; C069521:recombinant human tumor necrosis factor-binding protein-1